TG Therapeutics

is a biopharmaceutical company focused on the development of
novel treatments for B-cell malignancies and autoimmune diseases.

Click for full image >>

For Investors

NASDAQ: TGTX

News & Events

4.24.18

TG Therapeutics Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab (TG-1101) in Patients with Multiple Sclerosis at the American Academy of Neurology 70th Annual Meeting

4.18.18

TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company's BET Inhibitor, TG-1601, at the 2018 American Association for Cancer Research (AACR) Annual Meeting

Quick Links